VIVUS to Present at Two Upcoming Investor Conferences

Dec 03, 2010, 07:00 ET from VIVUS, Inc.

MOUNTAIN VIEW, Calif., Dec. 3, 2010 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that senior management will present an overview of the company at two investment conferences during the month of December.

The conference presentation schedule is as follows:




Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference


December 8, 2010 at 12:30 p.m. PT


Nikko Hotel, San Francisco, CA


Presenter: Charles Bowden, MD, director of clinical development




2010 Deutsche Bank BioFEST Conference


December 14, 2010 at 4:05 p.m. ET


Four Seasons Hotel, Boston, MA


Presenter: Timothy Morris, chief financial officer



A live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development is QNEXA®, which also is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

CONTACT:  






VIVUS, Inc.

Investor Relations:

The Trout Group

Timothy E. Morris


Brian Korb

Chief Financial Officer


bkorb@troutgroup.com

650-934-5200


646-378-2923



SOURCE VIVUS, Inc.



RELATED LINKS

http://www.vivus.com